Rehmann Capital Advisory Group Has $656,000 Holdings in Bristol-Myers Squibb Co (BMY)

Share on StockTwits

Rehmann Capital Advisory Group lessened its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 12.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,562 shares of the biopharmaceutical company’s stock after selling 1,537 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Bristol-Myers Squibb were worth $656,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in BMY. SFE Investment Counsel lifted its position in shares of Bristol-Myers Squibb by 8.6% during the 3rd quarter. SFE Investment Counsel now owns 16,375 shares of the biopharmaceutical company’s stock valued at $1,017,000 after acquiring an additional 1,290 shares during the period. Benedict Financial Advisors Inc. lifted its position in shares of Bristol-Myers Squibb by 4.0% during the 3rd quarter. Benedict Financial Advisors Inc. now owns 25,248 shares of the biopharmaceutical company’s stock valued at $1,567,000 after acquiring an additional 974 shares during the period. Toronto Dominion Bank lifted its position in shares of Bristol-Myers Squibb by 19.1% during the 2nd quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock valued at $58,813,000 after acquiring an additional 170,360 shares during the period. Aperio Group LLC lifted its position in shares of Bristol-Myers Squibb by 9.9% during the 3rd quarter. Aperio Group LLC now owns 928,404 shares of the biopharmaceutical company’s stock valued at $57,635,000 after acquiring an additional 83,708 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its position in shares of Bristol-Myers Squibb by 1.9% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock valued at $6,830,000 after acquiring an additional 2,323 shares during the period. 72.74% of the stock is currently owned by institutional investors.

Shares of Bristol-Myers Squibb stock opened at $53.08 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.40. Bristol-Myers Squibb Co has a 1 year low of $46.94 and a 1 year high of $70.05. The company has a market cap of $86.91 billion, a P/E ratio of 17.63, a P/E/G ratio of 1.48 and a beta of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.91 by $0.18. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. On average, analysts forecast that Bristol-Myers Squibb Co will post 3.87 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 1st. Investors of record on Friday, January 4th will be given a dividend of $0.41 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. This represents a $1.64 annualized dividend and a dividend yield of 3.09%. The ex-dividend date is Thursday, January 3rd. Bristol-Myers Squibb’s payout ratio is currently 53.16%.

A number of equities research analysts have recently issued reports on BMY shares. Citigroup downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $62.00 to $57.00 in a research report on Monday, October 22nd. JPMorgan Chase & Co. lifted their price target on shares of Bristol-Myers Squibb from $70.00 to $74.00 and gave the company an “overweight” rating in a research report on Monday, October 8th. Credit Suisse Group reiterated a “hold” rating and set a $61.00 price target on shares of Bristol-Myers Squibb in a research report on Wednesday, September 12th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, October 1st. Finally, William Blair reiterated an “outperform” rating on shares of Bristol-Myers Squibb in a research report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $61.95.

TRADEMARK VIOLATION NOTICE: “Rehmann Capital Advisory Group Has $656,000 Holdings in Bristol-Myers Squibb Co (BMY)” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://baseballnewssource.com/2018/12/08/rehmann-capital-advisory-group-has-656000-holdings-in-bristol-myers-squibb-co-bmy/3064281.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Further Reading: Market Capitalization

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.